摘要
目的 研究趋化因子CCL5在涎腺腺样囊性癌(salivaryadenoid cystic carcinoma,SACC)患者肿瘤组织和血清中的表达及临床意义。方法 收集SACC患者76例术前血清样本、手术中肿瘤组织和癌旁腮腺组织病理切片,32例体检健康对照者血清样品。应用免疫组织化学法检测CCL5及其受体CCR5蛋白在SACC肿瘤和癌旁组织中的表达,ELISA法检测血清CCL5水平。结果 SACC肿瘤组织中CCL5和CCR5表达水平明显高于癌旁组织,且差异均具有统计学意义(P<0.001)。观察组血清中CCL5的表达量为(8.43±1.36)ng/ml,显著高于对照组的(1.11±0.78)ng/ml(P<0.001)。不同肿瘤发生部位的患者血清CCL5水平间差异无统计学意义(P>0.05);不同组织学分型、淋巴结转移情况、肿瘤TMN分期的患者间血清CCL5水平差异具有统计学意义(P<0.05)。血清CCL5水平与肿瘤组织中CCL5蛋白表达呈正相关(γ=0.742,P<0.001),与肿瘤细胞中CCR5蛋白表达亦呈正相关(γ=0.799,P<0.001)。结论 趋化因子CCL5的异常表达可能在SACC的发生与发展过程中起重要作用,并有可能作为临床上SACC早期监测指标。
Objective To study the expression and clinical significance of chemokine CCL5 in tumor tissue and serum of salivary adenoid cystic carcinoma. Methods The serum samples of 76 patients with SACCOur hospital,were collected.Detection of CCL5 and its receptor CCR5 protein in SACC tumor and paracancerous tumor by immunohistochemical method The level of serum CCL5 was detected by Elisa. Results The expression levels of CCL5 and CCR5 in the tumor tissues were significantly higher than those of the paracancerous tissues ( P <0.001).The expression of CCL5 in serum of the observation group was significantly higher than that of the control group (8.43±1.36)ng/ml vs (1.11±0.78)ng/ml vs (1.11±0.78)ng/ml, P <0.05.There was no significant difference in serum CCL5 levels among patients with different tumor sites ( P >0.05).There was significant difference in serum CCL5 level between patients with TMN staging ( P <0.05).The level of serum CCL5 was positively correlated with the expression of CCL5 protein in tumor tissues ( P <0.742, P <0.05).The expression of CCR5 protein was positively correlated with the expression of CCR5 protein in tumor cells ( P <0.05, P <0.05, P <0.05). Conclusion The abnormal expression of chemokine CCL5 may play an important role in the occurrence and development of SACC,and may be used as an early clinical monitoring index for SACC.
作者
达成利
帕拉提·艾斯卡
比力克孜·玉素甫
DA Chengli;Palati·aisika;Bilikezi·yushufu(First People's Hospital,Kashi,844000)
出处
《实用癌症杂志》
2019年第6期891-894,共4页
The Practical Journal of Cancer